Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 18/20 | 0.44 |
| ▸ | PPARD | Q03181 | 11/20 | 0.42 |
| ▸ | PPARG | P37231 | 11/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579473 | 0.88 | LDHA (0.47) | PPARAPPARDPPARG | |
| SCHEMBL27711609 | 0.84 | LDHA (0.39) | PPARAPPARDPPARGEPHX2 | |
| SCHEMBL2502819 | 0.81 | PPARA (0.47) | PPARAPPARDPPARGEPHX2 | |
| SCHEMBL2502297 | 0.78 | THRB (0.39) | — | |
| SCHEMBL27711587 | 0.76 | LPAR1 (0.41) | PPARG | |
| SCHEMBL2502323 | 0.76 | KDM4E (0.34) | — | |
| SCHEMBL2500529 | 0.75 | CYP4F2 (0.46) | — | |
| SCHEMBL2502702 | 0.72 | CSNK2A1 (0.31) | — | |
| SCHEMBL15709565 | 0.70 | PPARG (0.48) | PPARAPPARDPPARGEPHX2 | |
| SCHEMBL1930862 | 0.70 | PPARG (0.48) | PPARAPPARDPPARGEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813613-B1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-8030327-B2 | 3-[1-(2-chlorophenyl)ethoxy]-5-imidazo[1,2-a]pyridin-3-ylthiophene-2-carboxyamide; polo like kinase inhibitor; antitumor and anticarcinogenic agent; mitotic phase (M phase) of the cell cycle | MDS K.K. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080103136-A1 | Novel Fused Imidazole Derivative | MSD K.K. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1813613-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103136-A1 | Novel Fused Imidazole Derivative | HRH4, H1-4, H1-3 | PPARA 4269/4885PPARD 4081/4885PPARG 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.